Table of Contents Table of Contents
Previous Page  673 / 812 Next Page
Information
Show Menu
Previous Page 673 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S669

EV1001

The practitioner cope with adverse

events on atypical antipsychotics:

About 63 patients with schizophrenia

I. Berrahal

1 ,

, R. Triki

1

, R. Chebbi

2

, B. Ghanjati

1

, R. Ghachem

1

1

Razi Hospital, Pinel, Mannouba, Tunisia

2

Centre Hospitalier Universitaire Vaudois, Médecine et psychiatarie

pénitentiaires, Lausanne, Switzerland

Corresponding author.

Introduction

The propensity of atypical antipsychotics (AAP) for

having a therapeutic effectwith fewer side effects and the balancing

of these supposed benefits with tolerance are the subject of many

studies.

Aims and objectives

We focused on adverse drug events (ADEs),

occurred under AAP, in a population of patients with schizophrenia

to assess the prevalences and describe how the practitioner deal

with these ADEs.

Methods

We have used a retrospective and descriptive study of

63 Tunisian patients with schizophrenia, consulting in the adult

outpatient of Razi hospital and treated by one type of AAP. The study

periodwas 6 months from the 1st January 2015. We used the Birch-

wood Insight Scale (BIS), Positive and Negative Syndrome Scale

(PANSS) and Udvalg for Kliniske Undersogelser (UKU) to assess the

insight, psychotic symptoms and ADEs.

Results

Twenty-four patients were on risperidone, 22 on olanza-

pine, 8 on amisulpride and 9 on clozapine. Antiparkinsonism drug

(15.9%)was associated because of neurological ADEsmainly Parkin-

sonism. Asthenia had a prevalence of 20.6%. Hypersalivation and

palpitation were estimated at 7.9% both. Weight gain’s prevalence

was 25.4%, including 1 case associated with hypercholesterolemia

and 1 case of unbalanced non-insulin-dependent diabetes. The

erectile dysfunction’s prevalence was 36.3% and decreased libido

27%. There were 2 cases of neutropenia and thrombocytopenia. The

management of these ADEs was observed when they moderately

began to influence the patient’s daily activity.

Conclusion

ADEs must be subject to an appropriate treatment

and if necessary resort to a specialist consultation to confirm or

deny imputability to AAP.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1986

EV1002

Do I need treatment? Insight and

therapy adherence in a group of

patients in treatment with

aripiprazole long acting injectable

S. Berta

1 ,

, C. Víctor

1

, T. Ivan

2

, M. Julia

1

, O. Silvia

3

, C. Sandra

3

,

M. Estanislao

3

, M. Luis Miguel

4

, B. Noelia

5

1

Parc de Salut Mar, INAD, Hospital del Mar, Barcelona, Spain

2

Parc de Salut Mar, INAD, Barcelona, Spain

3

Parc de Salut Mar, INAD-CSMA, Santa Coloma de Gramanet, Spain

4

Parc de Salut Mar, INAD-CSMA, Barcelona, Spain

5

Parc de Salut Mar, INAD-CAEM, Santa Coloma de Gramanet, Spain

Corresponding author.

Introduction

Relapse prevention is one of the major goals in

psychiatry because it will mark the prognosis and quality of life

in patients. In this aspect, plays a very important role insight

and adherence to treatment. Some studies show that long acting

injectable treatments improve adherence as compared with oral

medications.

Objective

The objective of this study is to analyse the degree of

insight and adherence to treatment of a group of patients with

aripiprazole long acting injectable ALAI treatment.

Methodology

Descriptive study in a group of patients treated

with ALAI. Three months of follow-up. To assess the insight we had

use the 3 first items of the Unawareness of Mental Disorder SUMD.

Adherence to treatment is evaluated bymonitoring if patients come

to administrate ALAI.

Results n

= 6, 2 women (33.3%) and 4 men (66.7%). The mean

age of the sample was 37 years. Diagnoses were 4 patients with

psychotic disorder (66.7%;) 2 with bipolar disorder (33.3%). At the

SUMD, mean score for the items consciousness of having a disor-

der and awareness of the effects of medication was 3, and for the

item awareness of the social consequences of mental disorder 4.

The mean score for the total punctuation was 10. Five (83.3%) had

a 100% of adherence, just 1 patient discontinued de treatment on

the third month.

Conclusions

On our sample adherence, it was almost complete

in all patients. To highlight the scores for SUMD which means low

insight. A large sample is required to increase the reliability of the

study.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1987

EV1003

Assessing quality of life following

long-acting injection treatment: 4

cases register

C.M. Calahorro

, M. Guerrero Jiménez , J.C. Navarro Barrios

Hospital Santa Ana, Unidad de Salud Mental, Motril, Spain

Corresponding author.

Introduction

Quality of life is defined by the World Health Orga-

nization as “Individuals’ perceptions of their position in life in the

context of the culture and value systems in which they live, and

in relation to their goals, expectations, standards, and concerns.”

Schizophrenia is a severe, disabling, lifelong disorder, associated

with severe social and occupational dysfunction. Aripiprazole Long

Acting Injection (LAI) is indicated for maintenance schizophre-

nia treatment in adult patients stabilised with oral aripiprazole.

It is the fourth second-generation antipsychotic depot formulation

approved for treating schizophrenia.

Objectives

Assessing quality of life in 4 patients treatedwith arip-

iprazole LAI.

Methods

In this paper, we evaluate of quality of life in 4 subjects

with diagnosis of paranoid schizophrenia (less 10 years of diagnos-

tic), male, age between 42 and 50 years, with poor adherence to oral

treatment. These patients received aripirazol LAI 400mg/month.

We evaluate quality of life at baseline and after 3 months. We

used the Quality of Life Scale (QOLS) and WHO-Quality of Life-Bref

(WHOQOL-BREF).

Results

Results demonstrated significant greater improvements

in all QLS scores. No significant changes in theWHOQOL-BREF total,

but improvement in subscale scores.

Conclusion

Quality of life in schizophrenia is adversely influ-

enced by the presence of clinical symptoms, especially negative

and depressive. Depot medications can improve treatment adher-

ence, however, long-term antipsychotic use can lead to irreversible

adverse effects (dyskinesias), which in some cases were reduced

by using newer antipsychotics (risperidone, paliperidone, aripipra-

zole). Aripiprazole LAI can be useful to improve quality of life.

Further methodologically robust studies are needed to generate

evidence-based conclusions.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1988